相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer
Barbara Melosky et al.
ONCOLOGIST (2020)
Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort
Neal E. Ready et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial
A. S. Mansfield et al.
ANNALS OF ONCOLOGY (2020)
Antibodies for the Treatment of Brain Metastases, a Dream or a Reality?
Marco Cavaco et al.
PHARMACEUTICS (2020)
YAP1 positive small-cell lung cancer subtype is associated with the T-cell inflamed gene expression profile and confers good prognosis and long term survival.
Taofeek Kunle Owonikoko et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study
Charles M. Rudin et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032
Neal Ready et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study
T. K. Owonikoko et al.
ANNALS OF ONCOLOGY (2019)
Emerging therapies for small cell lung cancer
Sen Yang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Immune Checkpoint Inhibitors in Small Cell Lung Cancer: A Partially Realized Potential
Samantha A. Armstrong et al.
ADVANCES IN THERAPY (2019)
Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial
Willemijn S. M. E. Theelen et al.
JAMA ONCOLOGY (2019)
Integration of radiotherapy and immunotherapy for treatment of oligometastases
Sean P. Pitroda et al.
LANCET ONCOLOGY (2019)
Carboplatin-Etoposide Versus Topotecan as Second-Line Treatment for Sensitive Relapsed Small-Cell Lung Cancer: Phase 3 Trial
N. Baize et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Luis Paz-Ares et al.
LANCET (2019)
The role of immunotherapy in small cell lung cancer
A. Calles et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2019)
Tumor mutational burden standardization initiatives: Recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions
Albrecht Stenzinger et al.
GENES CHROMOSOMES & CANCER (2019)
Immunotherapy in extensive small cell lung cancer
Vaibhav Verma et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2019)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
L. Horn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Clinical activity, safety and predictive biomarkers results from a phase Ia atezolizumab (atezo) trial in extensive-stage small cell lung cancer (ES-SCLC)
L.V. Sequist et al.
ANNALS OF ONCOLOGY (2017)
Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study
Patrick A. Ott et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
State-of-the-art considerations in small cell lung cancer brain metastases
Rimas V. Lukas et al.
ONCOTARGET (2017)
Comparison of Amrubicin and Weekly Cisplatin/Etoposide/Irinotecan in Patients With Relapsed Small-cell Lung Cancer
Hitomi Sumiyoshi Okuma et al.
CLINICAL LUNG CANCER (2017)
Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Pointed Progress in Second-Line Advanced Non-Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition
Barbara Melosky et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
Scott J. Antonia et al.
LANCET ONCOLOGY (2016)
Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline
Charles M. Rudin et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Immune Checkpoint Blockade in Cancer Therapy
Michael A. Postow et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial
Ben J. Slotman et al.
LANCET (2015)
Comprehensive genomic profiles of small cell lung cancer
Julie George et al.
NATURE (2015)
Second-Line Therapy of Small-Cell Lung Cancer: Topotecan Compared to a Combination Treatment with Adriamycin, Cyclophosphamide And Vincristine (ACO) - a Single Center Experience
Raphael Hagmann et al.
JOURNAL OF CANCER (2015)
Second-line combination therapies in nonsmall cell lung cancer without known driver mutations
Maria-Virginia Bluthgen et al.
EUROPEAN RESPIRATORY REVIEW (2015)
Third-Line Chemotherapy in Small-Cell Lung Cancer: An International Analysis
Demetrios Simos et al.
CLINICAL LUNG CANCER (2014)
Immunologic and Clinical Effects of Targeting PD-1 in Lung Cancer
R. D. Harvey
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
M. Frueh et al.
ANNALS OF ONCOLOGY (2013)
SEOM clinical guidelines for the treatment of small-cell lung cancer 2013
M. Domine Gomez et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2013)
Outcome of small cell lung cancer (SCLC) patients with brain metastases in a routine clinical setting
Mirko Lekic et al.
RADIOLOGY AND ONCOLOGY (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Outcomes of second-line chemotherapy in patients with relapsed extensive small cell lung cancer
Sandra Froeschl et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
An antigen-specific pathway for CD8 T cells across the blood-brain barrier
Ian Galea et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2007)
Small cell lung cancer: Current therapy and promising new regimens
SH Okuno et al.
ONCOLOGIST (2002)
分享论文
